Share

August 06, 2019; 93 (6) Editorial

Use of gadolinium for MRI diagnostic or surveillance studies in patients with MS

Lukas Haider, Robert T. Naismith, Alex Rovira
First published July 8, 2019, DOI: https://doi.org/10.1212/WNL.0000000000007891
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
208

Share

Article Information

vol. 93 no. 6 239-240
DOI: 
https://doi.org/10.1212/WNL.0000000000007891
PubMed: 
31285397
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published July 8, 2019.

Article Versions

Copyright & Usage: 
© 2019 American Academy of Neurology

Author Disclosures

    1. Lukas Haider,
    2. Robert T. Naismith and
    3. Alex Rovira
  1. Lukas Haider,
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. ESNR (European Society of Neuro-radiology) Research Fellowship ECTRIMS-MAGNIMS Research Fellowship

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Robert T. Naismith and
    3. Scientific Advisory Boards:

    1. 1) Alkermes

    Gifts:

    1. NONE

    Funding for travel or speaker honoraria:

    1. 1) Acorda Therapeutics, speaker honoraria and travel (commercial) 2) Alkermes, consulting and travel (commercial) 3) Celgene, consulting and travel (commercial) 4) Biogen IDEC, speaker honoraria and travel (commercial) 5) Genentech, speaker honoraria and travel (commercial) 6) Genzyme Corporation, speaker honoraria and travel (commercial) 7) EMD Serono, consulting honoraria and travel (commercial) 8) Novartis, consulting honoraria and travel (commercial) 9) TG Therapeutics, consulting honoraria (commercial) 10 Alexion, consulting honoraria (commercial)

    Editorial Boards:

    1. Journal Watch 2010-present, Associate Editor

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. 1) Acorda Therapeutics (commercial) 2) EMD Serono (commercial) 3) Genzyme Corporation (commercial) 4) Genentech (commercial) 5) Novartis (commercial)

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. National MS Society National Institutes of Health

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Alex Rovira
    4. Scientific Advisory Boards:

    1. (1) Novartis, (2) Biogen, (3) Genzyme, (4) OLEA Medical, (5) Icometrix, (6) Synthetic MRI, (7) Bayer

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. (1) Bayer, (2) Teva Pharmaceutical Industries Ltd, (3) Genzyme, (4) Bracco, (5) Merck-Serono, (6) Biogen Idec, (7) OLEA Medical, (8) Roche

    Editorial Boards:

    1. Editorial boards of:(1) Am J Neuroradiol. Editorial board member, 2008 at present;(2) Neuroradiology. Editorial board member, 2006 at present;(3) European Radiology, 2016 at present

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. (1) Bayer, (2) Teva Pharmaceutical Industries Ltd, (3) Genzyme, (4) Bracco, (5) Merck-Serono, (6) Biogen Idec, (7) OLEA Medical, (8) Stendhal, (9) Roche

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the NMR Research Unit (L.H.), Queens Square MS Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Science, University College London, UK; Department of Biomedical Imaging and Image Guided Therapy (L.H.), Medical University of Vienna, Austria; Washington University School of Medicine (R.T.N.), Saint Louis, MO; and Section of Neuroradiology, Department of Radiology (A.R.), University Hospital Vall d'Hebron, Barcelona, Spain.
  1. Correspondence
    Dr. Haider l.haider{at}ucl.ac.uk
View Full Text

Article usage

Article usage: July 2019 to March 2021

AbstractFullPdfSource
Jul 2019332232Highwire
Aug 201959212171Highwire
Sep 2019701019Highwire
Oct 20199264Highwire
Nov 20199128Highwire
Dec 2019138311Highwire
Jan 202070311Highwire
Feb 20204128Highwire
Mar 20202916Highwire
Apr 20205724Highwire
May 20204923Highwire
Jun 20202914Highwire
Jul 20202220Highwire
Aug 20202508Highwire
Sep 20203321Highwire
Oct 20203603Highwire
Nov 20202923Highwire
Dec 20201713Highwire
Jan 20212606Highwire
Feb 20212321Highwire
Mar 20213702Highwire

Cited By...

Disputes & Debates: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Disputes & Debates Submission Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

Topics Discussed

Alert Me